<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kalozoumi, G.</style></author><author><style face="normal" font="default" size="100%">Kel-Margoulis, O.</style></author><author><style face="normal" font="default" size="100%">Vafiadaki, E.</style></author><author><style face="normal" font="default" size="100%">Greenberg, D.</style></author><author><style face="normal" font="default" size="100%">Bernard, H.</style></author><author><style face="normal" font="default" size="100%">Soreq, H.</style></author><author><style face="normal" font="default" size="100%">Depaulis, A.</style></author><author><style face="normal" font="default" size="100%">Sanoudou, D.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Glial responses during epileptogenesis in Mus musculus point to potential therapeutic targets</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS OnePLoS OnePLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PloS one</style></alt-title><short-title><style face="normal" font="default" size="100%">PloS onePloS one</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Anticonvulsants/*pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Death/drug effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">computer simulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Epilepsy, Temporal Lobe/*drug therapy/immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation/drug effects</style></keyword><keyword><style  face="normal" font="default" size="100%">Hippocampus/drug effects/immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Kainic Acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style  face="normal" font="default" size="100%">MicroRNAs/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Neuroglia/*drug effects/immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Status Epilepticus/*drug therapy/immunology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year></dates><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">e0201742</style></pages><isbn><style face="normal" font="default" size="100%">1932-6203 (Electronic)1932-6203 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The Mesio-Temporal Lobe Epilepsy syndrome is the most common form of intractable epilepsy. It is characterized by recurrence of focal seizures and is often associated with hippocampal sclerosis and drug resistance. We aimed to characterize the molecular changes occurring during the initial stages of epileptogenesis in search of new therapeutic targets for Mesio-Temporal Lobe Epilepsy. We used a mouse model obtained by intra-hippocampal microinjection of kainate and performed hippocampal whole genome expression analysis at 6h, 12h and 24h post-injection, followed by multilevel bioinformatics analysis. We report significant changes in immune and inflammatory responses, neuronal network reorganization processes and glial functions, predominantly initiated during status epilepticus at 12h and persistent after the end of status epilepticus at 24h post-kainate. Upstream regulator analysis highlighted Cyba, Cybb and Vim as central regulators of multiple overexpressed genes implicated in glial responses at 24h. In silico microRNA analysis indicated that miR-9, miR-19b, miR-129, and miR-223 may regulate the expression of glial-associated genes at 24h. Our data support the hypothesis that glial-mediated inflammatory response holds a key role during epileptogenesis, and that microglial cells may participate in the initial process of epileptogenesis through increased ROS production via the NOX complex.</style></abstract><accession-num><style face="normal" font="default" size="100%">30114263</style></accession-num><notes><style face="normal" font="default" size="100%">Kalozoumi, GeorgiaKel-Margoulis, OlgaVafiadaki, ElizabethGreenberg, DavidBernard, HeleneSoreq, HermonaDepaulis, AntoineSanoudou, DespinaengResearch Support, Non-U.S. Gov't2018/08/17 06:00PLoS One. 2018 Aug 16;13(8):e0201742. doi: 10.1371/journal.pone.0201742. eCollection 2018.</style></notes><custom2><style face="normal" font="default" size="100%">6095496 GmbH (http://genexplain.com/) at the time of the study. This commercial affiliation does not alter our adherence PLOS ONE policies on sharing data and materials.</style></custom2><auth-address><style face="normal" font="default" size="100%">Clinical Genomics and Pharmacogenomics Unit, 4th Department of Internal Medicine, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.geneXplain GmbH, Wolfenbuttel, Germany.Molecular Biology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.The Edmond and Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.INSERM, Grenoble, France.Univ. Grenoble Alpes, Grenoble Institut des Neurosciences, Grenoble, France.CHU de Grenoble, Hopital Michallon, Grenoble, France.</style></auth-address></record></records></xml>